Search

Your search keyword '"Rossi, Davide"' showing total 3,090 results

Search Constraints

Start Over You searched for: Author "Rossi, Davide" Remove constraint Author: "Rossi, Davide"
3,090 results on '"Rossi, Davide"'

Search Results

101. A near-threshold RISC-V core with DSP extensions for scalable IoT Endpoint Devices

102. YodaNN: An Architecture for Ultra-Low Power Binary-Weight CNN Acceleration

103. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

104. Hodgkin Lymphoma: Recent Progress in Overall Management

105. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

106. Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1

108. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

109. Consistency and Availability in Microservice Architectures

110. Richter Syndrome

111. Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial

113. Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models

116. Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling

117. ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

119. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine

123. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

124. An Initial Investigation of Concurrency Bugs in Open Source Systems

125. Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide and rituximab (FCR) in patients with CLL. A retrospective multicenter 'real-world' study

126. HL-370 Fragmentóme Profiling Reveals Distinct Molecular Subgroups of Classic Hodgkin Lymphoma

127. Where are your Manners? Sharing Best Community Practices in the Web 2.0

129. Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma.

132. Jüngste Entwicklungen in der Hämatologie, Teil 2

133. Développements récents en hématologie, Partie 2

134. Targeting CD19-positive lymphomas with the antibody-drug conjugate (ADC) loncastuximab tesirine: preclinical evidence as single agent and as combinatorial approach

135. ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells

136. Développements récents en hématologie, Teil 1

137. Jüngste Entwicklungen in der Hämatologie, Teil 1

138. XPO1 mutations identify early‐stage CLL characterized by shorter time to first treatment and enhanced BCR signalling

140. P594: THE CXCR4-LOW/CD5-HIGH PROLIFERATIVE FRACTION IS ENRICHED IN BTK MUTATIONS AND ANTICIPATES RELAPSE IN IBRUTINIB-TREATED CLL

141. PB1938: REAL WORLD EFFECTIVENESS AND SAFETY OF VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN TREATMENT NAIVE CLL PATIENTS – DATA FROM THE OBSERVATIONAL STUDY VERVE

142. P597: XPO1 MUTATIONS IDENTIFY EARLY STAGE CLL CHARACTERIZED BY SHORTER TIME TO FIRST TREATMENT AND ENHANCED BCR SIGNALING

143. Graphene-based Wireless Agile Interconnects for Massive Heterogeneous Multi-chip Processors

144. P1225: CYLD, A NOVEL REGULATOR OF SPLENIC MARGINAL ZONE LYMPHOMA PATHOGENESIS

145. S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME

146. S143: NATURAL CLONAL EVOLUTION OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH BIMODAL CD49D EXPRESSION REVEALS CD49D PLASTICITY

Catalog

Books, media, physical & digital resources